Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more) Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics Inc LCTX

Healthcare Biotechnology
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and... see more

Recent & Breaking News (NYSEAM:LCTX)

BioTime, Inc. Announces Closing of Public Offering of Common Stock

Business Wire June 21, 2016

BioTime, Inc. Announces Pricing of Public Offering of Common Stock

Business Wire June 16, 2016

BioTime, Inc. Announces Proposed Public Offering of Common Stock

Business Wire June 15, 2016

BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD

Business Wire June 13, 2016

BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program

Business Wire June 10, 2016

BioTime to Present at the Jefferies 2016 Global Healthcare Conference

Business Wire June 9, 2016

BioTime to Present at Two Upcoming Investor Conferences

Business Wire May 20, 2016

BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments

Business Wire May 10, 2016

BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity, International Conference

Business Wire April 26, 2016

LifeMap Solutions Launches Full-Service Mobile Health App Design & Development to Meet the Needs of Medical, Research, and Commercial Partners

Business Wire April 25, 2016

BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK

Business Wire April 5, 2016

BioTime, Inc. to Host Conference Call to Update Investors on Recent Accomplishments and Corporate Objectives for 2016

Business Wire March 21, 2016

Asterias Biotherapeutics Appoints Stephen L. Cartt President and Chief Executive Officer

PR Newswire February 29, 2016

BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy in Acute Myeloid Leukemia

Business Wire February 24, 2016

BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents

Press Releases February 16, 2016

BioTime, Inc. to Present at Three Investor Conferences in February

Business Wire February 1, 2016

Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018

Business Wire January 12, 2016

OncoCyte Corporation Initiates Trading on the NYSE MKT

GlobeNewswire January 4, 2016

BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common Stock

Business Wire December 31, 2015

BioTime Announces "When-Issued" Trading of Subsidiary OncoCyte Corporation in Connection With Planned Distribution

Business Wire December 30, 2015